Source:http://linkedlifedata.com/resource/pubmed/id/17107895
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2006-11-19
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1042-8194
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2271-2
|
pubmed:meshHeading | |
pubmed:year |
2006
|
pubmed:articleTitle |
Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?
|
pubmed:affiliation |
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece. mdimop@med.uoa.gr
|
pubmed:publicationType |
Journal Article,
Comment
|